Fiona du Monceau

Fiona du Monceau joined ExeVir Bio in June 2020 as COO to help set-up, build the company and bring the lead molecule rapidly to patients. Prior to this, Fiona worked for UCB Ventures as a Venture Partner since 2018. UCB Ventures is a €150 million strategic corporate venture fund which was set up to invest in innovative, longer term and higher risk opportunities beyond UCB’s current focus areas. Her UCB career began in 2014 when she was appointed as Commercial Lead (bone) and Head of the Bone Patient Value Unit for Europe. In that role, she built the European country teams in preparation for the launch of UCB-Amgen's anti-sclerostin product, EVENITY.

Fiona has previously worked in Business Development for GlaxoSmithKline Biologicals in Belgium. In 2002, she moved to the US and worked at McKinsey & Company, based in their New Jersey office, covering healthcare clients in the US and Europe. From 2006 to 2014, she held several leadership roles at Eli Lilly contributing to the launches, new indications and relaunches of several drugs across different therapeutic areas (Neurology, Cardiovascular, Osteoporosis and Immunology), working with alliance partners, managing patient support programs and leading changes through patent exclusivities and new models.

Fiona graduated with a MSc in Management from the Solvay Business School (ULB) and an MBA from Harvard Business School (2006). She is a Fulbright Scholar and a Recipient of a Belgian American Education Foundation (BAEF) scholarship. She has been a board director at Medifin, a medical Imaging start-up, since 2015 and at the Financiere de Tubize since 2014. She is a governor of the London Business School since 2016 and a member of its audit and risk committee.